Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rozanolixizumab in LGI1 Autoimmune Encephalitis
NCT04875975Phase 2Terminated
- Sponsor
- UCB
- Start
- Sep 2021
- Primary completion
- Mar 2024
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 2 trial of rozanolixizumab in leucine-rich glioma-inactivated 1 antibody encephalitis, sponsored by UCB. Started Sep 2021; status: terminated.
02
Drugs
rozanolixizumab
03
Conditions
leucine-rich glioma-inactivated 1 antibody encephalitis
Beyond the preview
Go deeper on NCT04875975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04875975.